Cardium Therapeutics Inc., which could face possible suspension or removal from the New York Stock Exchange, has until Jan. 6, 2014 to submit an updated plan of compliance to the exchange. The updated plan would allow San Diego-based Cardium, which is a diversified holding company with a number of life sciences product lines, to regain compliance by May 30, 2014.
The notification received from the listing exchange had no current effect on the listing of the company’s shares on the exchange
Shares for Cardium (NYSE:CXM) closed at 75 cents on Dec. 20. It peaked at above $70 in 2007, when it was first listed on the New York Stock Exchange.